Baird Maintains Outperform on Bright Minds Biosciences, Lowers Price Target to $107
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Baird analyst Joel Beatty maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform and lowers the price target from $126 to $107.
Baird analyst Joel Beatty maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform and lowers the price target from $126 to $107.